Freenome vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Freenome is a biotech company developing AI-powered multiomics blood tests for early cancer detection; raised $1.1B+ total with Roche as a major investor; signed a $75M exclusive license with Exact Sciences for colorectal cancer;
About
Freenome is a clinical-stage biotechnology company founded in 2014 and headquartered in South San Francisco, California. The company is developing a multiomics blood-based testing platform for the early detection of cancer — combining genomics, proteomics, metabolomics, and epigenomics signals from a single blood draw and applying AI/ML models to distinguish cancer-derived signals from normal biological variation. Its lead program targets colorectal cancer (CRC) screening, aiming to provide a non-invasive alternative to colonoscopy for the millions of Americans who decline or delay guideline-based screening.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.